TNFSF10 and Alzheimer disease: To investigate whether NANO-A or NANO-B complexes were more effective in brain targeting compared to the free anti-TRAIL antibody, 12-month-old 3xTg-AD and age-matched wild-type mice were intranasally administered with anti-TRAIL antibody free (0.05 mg/mL; 200 μL/mouse) or conjugated with NANO-A or NANO-B NPs (50 μg/mL).